IFN-gamma transduced autologous tumor cells

IFN-gamma transduced autologous tumor cells is an experimental autologous cancer vaccine developed for the treatment of glioblastoma multiforme. The therapy involves harvesting tumor cells from a patient, genetically modifying them via transduction to express interferon-gamma (IFN-gamma), and then irradiating the cells to prevent further growth while maintaining their immunogenicity. When administered back to the patient (typically via intradermal or subcutaneous injection), these cells secrete IFN-gamma locally. This cytokine acts to enhance the expression of MHC molecules, improve antigen presentation by dendritic cells, and stimulate a robust T-cell-mediated immune response against the tumor-associated antigens present on the vaccine cells. Clinical studies at Lund University Hospital have demonstrated the safety of this approach and suggested a potential survival benefit in patients with malignant gliomas.

Other names

IFN-gamma-transduced autologous tumor cell vaccineIFN-gamma-secreting autologous tumor cells